Export Mendeley
＜journal article＞
Prevention and Management of Hepatitis B Virus Reactivation
| Creator | |
|---|---|
| Language | |
| Publisher | |
| Date | |
| Source Title | |
| Vol | |
| Issue | |
| First Page | |
| Last Page | |
| Publication Type | |
| Access Rights | |
| JaLC DOI | |
| Abstract | Globally, it is estimated that around 1 in every 3 individuals may have been exposed to hepatitis B virus(HBV) infection. In addition, population of 6％ are chronic carriers and over 600,000 people die... each year from acute hepatitis, liver cirrhosis or hepatocellular carcinoma due to HBV infection. Recently, HBV reactivation associated with immune-suppressive and biological therapies is emerging to be an important cause of morbidity and mortality in patients with prior exposure to HBV infection. With the advent of newer and emerging forms of cancer chemotherapy, immunosuppressive or biologic therapies, it has become important to understand the mechanisms whereby certain therapies are more prone to HBV reactivation. In this article, we summarize the mechanism of HBV reactivation associated with immune-suppressive and biological therapies.show more |
| Table of Contents | はじめに 1．B型肝炎の再活性化の病態・概要 2．国内外でのＢ型肝炎再活性化に対する対策 3．九州大学病院における現状と独自の対策 おわりに |
Hide fulltext details.
| File | FileType | Size | Views | Description |
|---|---|---|---|---|
p001
|
2.28 MB | 1,649 |
Details
| PISSN | |
|---|---|
| NCID | |
| Record ID | |
| Peer-Reviewed | |
| Subject Terms | |
| Type | |
| Created Date | 2019.05.21 |
| Modified Date | 2021.03.03 |